kabutan

PhoenixBio Co.,Ltd.(6190) Summary

6190
TSE Growth
PhoenixBio Co.,Ltd.
459
JPY
+12
(+2.68%)
Jan 29, 3:30 pm JST
3.00
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
16.9
PBR
1.37
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
447 JPY 2.91 USD
Previous Close Jan 28
447 JPY 2.92 USD
High Jan 29, 3:30 pm
459 JPY 3.00 USD
Low Jan 29, 9:25 am
436 JPY 2.84 USD
Volume
37,500
Trading Value
0.02B JPY 0.11M USD
VWAP
447.71 JPY 2.93 USD
Minimum Trading Value
45,900 JPY 300 USD
Market Cap
1.87B JPY 0.01B USD
Number of Trades
94
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
400
1-Year High Feb 25, 2025
13,787
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 288,600
Jan 16, 2026 0 276,300
Jan 9, 2026 0 270,900
Dec 26, 2025 0 275,500
Dec 19, 2025 0 295,000
Company Profile
PhoenixBio Co., Ltd. is a biotech venture originating from Hiroshima University, specializing in the production of PXB mice with high human hepatocyte replacement rates and contract testing services.
Sector
Services
PhoenixBio, a biotech venture spun off from Hiroshima University, primarily focuses on providing contract testing services for drug development using PXB mice. PXB mice are chimeric mice with livers largely replaced by human hepatocytes, used for predicting human metabolism and researching hepatitis viruses. The company's main services include pharmacokinetic studies, safety tests, and efficacy evaluations for hepatitis drugs. Additionally, PhoenixBio sells fresh human hepatocytes (PXB-cells) obtained from PXB mice. These services play a crucial role in the preclinical stages of new drug development, supporting pharmaceutical companies in their drug discovery research.